3mas › Citations

Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.

Yang B, Zhong C, Peng Y, Lai Z, Ding J
Cell Res 20 1188-200 (2010)
Related entries: 3map, 3mar

Cited: 74 times
EuropePMC logo PMID: 20975740

Abstract

Human cytosolic NADP-IDH (IDH1) has recently been found to be involved in tumorigenesis. Notably, the tumor-derived IDH1 mutations identified so far mainly occur at Arg132, and mutation R132H is the most prevalent one. This mutation impairs the oxidative IDH activity of the enzyme, but renders a new reduction function of converting α-ketoglutarate (αKG) to 2-hydroxyglutarate. Here, we report the structures of the R132H mutant IDH1 with and without isocitrate (ICT) bound. The structural data together with mutagenesis and biochemical data reveal a previously undefined initial ICT-binding state and demonstrate that IDH activity requires a conformational change to a closed pre-transition state. Arg132 plays multiple functional roles in the catalytic reaction; in particular, the R132H mutation hinders the conformational changes from the initial ICT-binding state to the pre-transition state, leading to the impairment of the IDH activity. Our results describe for the first time that there is an intermediate conformation that corresponds to an initial ICT-binding state and that the R132H mutation can trap the enzyme in this conformation, therefore shedding light on the molecular mechanism of the "off switch" of the potentially tumor-suppressive IDH activity. Furthermore, we proved the necessity of Tyr139 for the gained αKG reduction activity and propose that Tyr139 may play a vital role by compensating the increased negative charge on the C2 atom of αKG during the transfer of a hydride anion from NADPH to αKG, which provides new insights into the mechanism of the "on switch" of the hypothetically oncogenic reduction activity of IDH1 by this mutation.

Reviews - 3mas mentioned but not cited (1)

  1. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. Br J Cancer 122 1580-1589 (2020)

Articles - 3mas mentioned but not cited (5)

  1. Proteome-wide covalent ligand discovery in native biological systems. Backus KM, Correia BE, Lum KM, Forli S, Horning BD, González-Páez GE, Chatterjee S, Lanning BR, Teijaro JR, Olson AJ, Wolan DW, Cravatt BF. Nature 534 570-574 (2016)
  2. Structural, kinetic and chemical mechanism of isocitrate dehydrogenase-1 from Mycobacterium tuberculosis. Quartararo CE, Hazra S, Hadi T, Blanchard JS. Biochemistry 52 1765-1775 (2013)
  3. Identification of proximal SUMO-dependent interactors using SUMO-ID. Barroso-Gomila O, Trulsson F, Muratore V, Canosa I, Merino-Cacho L, Cortazar AR, Pérez C, Azkargorta M, Iloro I, Carracedo A, Aransay AM, Elortza F, Mayor U, Vertegaal ACO, Barrio R, Sutherland JD. Nat Commun 12 6671 (2021)
  4. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Dexter JP, Ward PS, Dasgupta T, Hosios AM, Gunawardena J, Vander Heiden MG. J Biol Chem 293 20051-20061 (2018)
  5. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate. Sesanto R, Kuehn JF, Barber DL, White KA. Biochemistry 60 1983-1994 (2021)


Reviews citing this publication (20)

  1. IDH1 and IDH2 mutations in gliomas. Cohen AL, Holmen SL, Colman H. Curr Neurol Neurosci Rep 13 345 (2013)
  2. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Golub D, Iyengar N, Dogra S, Wong T, Bready D, Tang K, Modrek AS, Placantonakis DG. Front Oncol 9 417 (2019)
  3. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE. Biochim Biophys Acta 1846 326-341 (2014)
  4. Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer. Akins NS, Nielson TC, Le HV. Curr Top Med Chem 18 494-504 (2018)
  5. The underappreciated role of allostery in the cellular network. Nussinov R, Tsai CJ, Ma B. Annu Rev Biophys 42 169-189 (2013)
  6. What do we know about IDH1/2 mutations so far, and how do we use it? Horbinski C. Acta Neuropathol 125 621-636 (2013)
  7. The role of IDH mutations in acute myeloid leukemia. Montalban-Bravo G, DiNardo CD. Future Oncol 14 979-993 (2018)
  8. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Guo C, Pirozzi CJ, Lopez GY, Yan H. Curr Opin Neurol 24 648-652 (2011)
  9. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Tommasini-Ghelfi S, Murnan K, Kouri FM, Mahajan AS, May JL, Stegh AH. Sci Adv 5 eaaw4543 (2019)
  10. 2-Hydroxyglutarate in Cancer Cells. Ježek P. Antioxid Redox Signal 33 903-926 (2020)
  11. Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers? van Lith SA, Navis AC, Verrijp K, Niclou SP, Bjerkvig R, Wesseling P, Tops B, Tops B, Molenaar R, van Noorden CJ, Leenders WP. Biochim Biophys Acta 1846 66-74 (2014)
  12. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Borodovsky A, Seltzer MJ, Riggins GJ. Curr Opin Oncol 24 83-89 (2012)
  13. Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. Romanidou O, Kotoula V, Fountzilas G. Cancer Genomics Proteomics 15 421-436 (2018)
  14. Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias. Testa U, Castelli G, Pelosi E. Cancers (Basel) 12 E2427 (2020)
  15. The molecular biology of WHO grade II gliomas. Marko NF, Weil RJ. Neurosurg Focus 34 E1 (2013)
  16. New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Shibahara I, Sonoda Y, Kanamori M, Saito R, Kumabe T, Tominaga T. Brain Tumor Pathol 28 203-208 (2011)
  17. Recent advances of IDH1 mutant inhibitor in cancer therapy. Tian W, Zhang W, Wang Y, Jin R, Wang Y, Guo H, Tang Y, Yao X. Front Pharmacol 13 982424 (2022)
  18. From Protein Film Electrochemistry to Nanoconfined Enzyme Cascades and the Electrochemical Leaf. Armstrong FA, Cheng B, Herold RA, Megarity CF, Siritanaratkul B. Chem Rev 123 5421-5458 (2023)
  19. Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. Roh J, Im M, Kang J, Youn B, Kim W. Anim Cells Syst (Seoul) 27 19-28 (2023)
  20. Mutant IDH in Gliomas: Role in Cancer and Treatment Options. Solomou G, Finch A, Asghar A, Bardella C. Cancers (Basel) 15 2883 (2023)

Articles citing this publication (48)

  1. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y. Cancer Cell 19 17-30 (2011)
  2. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE. Science 340 622-626 (2013)
  3. Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery. Merk A, Bartesaghi A, Banerjee S, Falconieri V, Rao P, Davis MI, Pragani R, Boxer MB, Earl LA, Milne JLS, Subramaniam S. Cell 165 1698-1707 (2016)
  4. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY. Oncogene 32 3091-3100 (2013)
  5. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. Leonardi R, Subramanian C, Jackowski S, Rock CO. J Biol Chem 287 14615-14620 (2012)
  6. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U. Nat Chem Biol 11 878-886 (2015)
  7. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, Rak A, Hoffmann D, Rooney E, Vassort A, Englaro W, Li Y, Patel V, Adrian F, Gross S, Wiederschain D, Cheng H, Licht S. J Biol Chem 290 762-774 (2015)
  8. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect. Xiang S, Gu H, Jin L, Thorne RF, Zhang XD, Wu M. Proc Natl Acad Sci U S A 115 E1465-E1474 (2018)
  9. The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. Smolková K, Ježek P. Int J Cell Biol 2012 273947 (2012)
  10. Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. Zheng B, Yao Y, Liu Z, Deng L, Anglin JL, Jiang H, Prasad BV, Song Y. ACS Med Chem Lett 4 542-546 (2013)
  11. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency. Avellaneda Matteo D, Grunseth AJ, Gonzalez ER, Anselmo SL, Kennedy MA, Moman P, Scott DA, Hoang A, Sohl CD. J Biol Chem 292 7971-7983 (2017)
  12. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, Poptodorov G, Mitev V, Kaneva R, Gabrovsky N. Biomed Res Int 2014 654727 (2014)
  13. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. Wu F, Jiang H, Zheng B, Kogiso M, Yao Y, Zhou C, Li XN, Song Y. J Med Chem 58 6899-6908 (2015)
  14. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. Liu Z, Yao Y, Kogiso M, Zheng B, Deng L, Qiu JJ, Dong S, Lv H, Gallo JM, Li XN, Song Y. J Med Chem 57 8307-8318 (2014)
  15. Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes. Walker OS, Elsässer SJ, Mahesh M, Bachman M, Balasubramanian S, Chin JW. J Am Chem Soc 138 718-721 (2016)
  16. Induced fit and the catalytic mechanism of isocitrate dehydrogenase. Gonçalves S, Miller SP, Carrondo MA, Dean AM, Matias PM. Biochemistry 51 7098-7115 (2012)
  17. Insight into novel RNA-binding activities via large-scale analysis of lncRNA-bound proteome and IDH1-bound transcriptome. Liu L, Li T, Song G, He Q, Yin Y, Lu JY, Bi X, Wang K, Luo S, Chen YS, Yang Y, Sun BF, Yang YG, Wu J, Zhu H, Shen X. Nucleic Acids Res 47 2244-2262 (2019)
  18. The β and γ subunits play distinct functional roles in the α2βγ heterotetramer of human NAD-dependent isocitrate dehydrogenase. Ma T, Peng Y, Huang W, Liu Y, Ding J. Sci Rep 7 41882 (2017)
  19. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q. Chen J, Yang J, Sun X, Wang Z, Cheng X, Lu W, Cai X, Hu C, Shen X, Cao P. Sci Rep 7 16458 (2017)
  20. IDH1 mutant structures reveal a mechanism of dominant inhibition. Zhao S, Guan KL. Cell Res 20 1279-1281 (2010)
  21. Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics. Xu Y, Liu L, Nakamura A, Someya S, Miyakawa T, Tanokura M. Sci Rep 7 9785 (2017)
  22. Functional relevance of dynamic properties of Dimeric NADP-dependent Isocitrate Dehydrogenases. Vinekar R, Verma C, Ghosh I. BMC Bioinformatics 13 Suppl 17 S2 (2012)
  23. Molecular mechanism of the allosteric regulation of the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase. Ma T, Peng Y, Huang W, Ding J. Sci Rep 7 40921 (2017)
  24. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J. Cancer Discov 9 756-777 (2019)
  25. Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production. Kotredes KP, Razmpour R, Lutton E, Alfonso-Prieto M, Ramirez SH, Gamero AM. Oncotarget 10 2675-2692 (2019)
  26. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Chaturvedi A, Goparaju R, Gupta C, Weder J, Klünemann T, Araujo Cruz MM, Kloos A, Goerlich K, Schottmann R, Othman B, Struys EA, Bähre H, Grote-Koska D, Brand K, Ganser A, Preller M, Heuser M. Leukemia 34 416-426 (2020)
  27. Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1. Liu S, Abboud MI, John T, Mikhailov V, Hvinden I, Walsby-Tickle J, Liu X, Pettinati I, Cadoux-Hudson T, McCullagh JSO, Schofield CJ. Commun Biol 4 1243 (2021)
  28. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Zheng M, Sun W, Gao S, Luan S, Li D, Chen R, Zhang Q, Chen L, Huang J, Li H. Oncotarget 8 44255-44265 (2017)
  29. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Verdura S, Cuyàs E, Lozano-Sánchez J, Bastidas-Velez C, Llorach-Parés L, Fernández-Arroyo S, Hernández-Aguilera A, Joven J, Nonell-Canals A, Bosch-Barrera J, Martin-Castillo B, Vellon L, Sanchez-Martinez M, Segura-Carretero A, Menendez JA. Carcinogenesis 40 27-40 (2019)
  30. Identification and analysis of mutational hotspots in oncogenes and tumour suppressors. Baeissa H, Benstead-Hume G, Richardson CJ, Pearl FMG. Oncotarget 8 21290-21304 (2017)
  31. Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1. Law JM, Stark SC, Liu K, Liang NE, Hussain MM, Leiendecker M, Ito D, Verho O, Stern AM, Johnston SE, Zhang YL, Dunn GP, Shamji AF, Schreiber SL. ACS Med Chem Lett 7 944-949 (2016)
  32. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. Avellaneda Matteo D, Wells GA, Luna LA, Grunseth AJ, Zagnitko O, Scott DA, Hoang A, Luthra A, Swairjo MA, Schiffer JM, Sohl CD. Biochem J 475 3221-3238 (2018)
  33. Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase. Sun P, Liu Y, Ma T, Ding J. Cell Discov 6 94 (2020)
  34. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells. Chen J, Yang J, Wei Q, Weng L, Wu F, Shi Y, Cheng X, Cai X, Hu C, Cao P. Cell Commun Signal 18 55 (2020)
  35. Molecular basis for the function of the αβ heterodimer of human NAD-dependent isocitrate dehydrogenase. Sun P, Ma T, Zhang T, Zhu H, Zhang J, Liu Y, Ding J. J Biol Chem 294 16214-16227 (2019)
  36. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients. Acquaviva G, Visani M, de Biase D, Marucci G, Franceschi E, Tosoni A, Brandes AA, Rhoden KJ, Pession A, Tallini G. Sci Rep 8 4459 (2018)
  37. Structure of a highly NADP+-specific isocitrate dehydrogenase. Sidhu NS, Delbaere LT, Sheldrick GM. Acta Crystallogr D Biol Crystallogr 67 856-869 (2011)
  38. Crystal structure studies of NADP+ dependent isocitrate dehydrogenase from Thermus thermophilus exhibiting a novel terminal domain. Kumar SM, Pampa KJ, Manjula M, Abdoh MM, Kunishima N, Lokanath NK. Biochem Biophys Res Commun 449 107-113 (2014)
  39. Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. Lyu J, Liu Y, Gong L, Chen M, Madanat YF, Zhang Y, Cai F, Gu Z, Cao H, Kaphle P, Kim YJ, Kalkan FN, Stephens H, Dickerson KE, Ni M, Chen W, Patel P, Mims AS, Borate U, Burd A, Cai SF, Yin CC, You MJ, Chung SS, Collins RH, DeBerardinis RJ, Liu X, Xu J. Cancer Discov 13 170-193 (2023)
  40. IDH1 fine-tunes cap-dependent translation initiation. Liu L, Lu JY, Li F, Xing X, Li T, Yang X, Shen X. J Mol Cell Biol 11 816-828 (2019)
  41. Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach. Juritz EI, Bascur JP, Almonacid DE, González-Nilo FD. Mol Diagn Ther 22 369-380 (2018)
  42. Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication. Song P, Wei H, Cao Z, Wang P, Zhu G. PLoS One 9 e115025 (2014)
  43. Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity. Chambers JM, Miller W, Quichocho G, Upadhye V, Matteo DA, Bobkov AA, Sohl CD, Schiffer JM. Biochemistry 59 479-490 (2020)
  44. NADP(H)-dependent biocatalysis without adding NADP(H). Herold RA, Reinbold R, Schofield CJ, Armstrong FA. Proc Natl Acad Sci U S A 120 e2214123120 (2023)
  45. Point mutation (R153H or R153C) in Escherichia coli isocitrate dehydrogenase: Biochemical characterization and functional implication. Song P, Li S, Wu Y, Lv C, Wang P, Zhu G. J Basic Microbiol 57 41-49 (2017)
  46. Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1. Kitago Y, Kaneko MK, Ogasawara S, Kato Y, Takagi J. Biochem Biophys Res Commun 478 1274-1279 (2016)
  47. Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using Hydrogen-Deuterium Exchange Mass Spectrometry. Sabo KA, Albekioni E, Caliger D, Coleman NJ, Thornberg E, Avellaneda Matteo D, Komives EA, Silletti S, Sohl CD. Biochemistry 62 1145-1159 (2023)
  48. Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening. Hu C, Zeng Z, Ma D, Yin Z, Zhao S, Chen T, Tang L, Zuo S. Front Pharmacol 13 982375 (2022)


Quick links